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Background: Head and neck cancers are a heterogeneous group of malignancies, affecting various sites and
subsites, with differing prognoses. The aim of this study was to analyse survival for European head and neck cancer
patients in populations covered by population-based cancer registries (CRs), in relation to tumour subsite as
prognostic factor.
Patients and methods: We analysed 51 912 adult head and neck cancer cases (36 322 mouth–pharynx and
15 590 larynx) diagnosed from 1995 to 1999 and archived by 45 CRs in 20 countries participating in EUROCARE-4.
Five-year age-standardised relative survival was estimated for mouth–pharynx and larynx sites by sex and country.
Relative survival was modelled to provide estimates of relative excess risks (RERs) of death by country, adjusted for
confounding factors.
Results: A large but site-variable proportion of tumours were incompletely specified. Five-year age-standardised
relative survival was low in Slovakia and high in The Netherlands. Adjustment for subsite reduced RERs of death for
most countries; 5-year relative survival increased from 1990–1994 to 1995–1999 for all subsites, while between-
country differences in survival narrowed.
Conclusion: Differences in subsite distribution explain a considerable part of the survival differences for head and
neck cancers, however, incomplete/inaccurate subsite reporting complicate interpretation.
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introduction
Head and neck cancers are a heterogeneous group of
malignancies, affecting various sites and subsites, with a range
of histologies and etiological factors. The incidence of cancers
of the mouth and pharynx (excluding nasopharynx) in Europe
was estimated in 2002 at 93 500 cases, almost 75% of which
were in men. Age-standardised rates were high in men in
Western Europe (21 of 100 000 man-year) followed by
Southern and Eastern Europe (14 of 100 000 man-year) and
lower in Northern Europe (8 of 100 000 man-year) [1].
Laryngeal cancer, with 45 500 new cases in Europe in 2002, is
also more common in men, with a sex ratio of almost 7 : 1.
Age-standardised rates for men are among the highest in the
world in Southern Europe (10.9 of 100 000 person-year) and
Eastern Europe (9.2 of 100 000 person-year), somewhat lower
in Western Europe (7.2 of 100 000 person-year) and
considerably lower in Northern Europe (4.2 of 100 000 person-
year) [1].
This marked geographic variation reflects variation in risk
factors for these diseases, which is in turn related to lifestyle [2].
The main risk factors for head and neck cancers are tobacco
and alcohol use, but diet is also important [3, 4]. High
consumption of fruit and vegetables, and a Mediterranean diet,
has been associated with better prognoses for laryngeal cancer
[5]. It has also been shown recently that human papillomavirus
(HPV) infection is a risk factor for some head and neck
cancers including those of the tongue base and tonsil [6].
Patients with HPV-related head and neck cancers are younger
and may have prognoses that differ from those of non-HPV-
related cancers [7, 8].
Site and subsite are important determinants of prognosis [9].
The complex anatomy of the head and neck region results in
complex patterns of local and regional invasion, often making it
difficult to establish the exact subsite of origin. Over the last 20
years, surgical and radiotherapy techniques, and also
chemotherapy agents, have changed markedly, in attempts to
reduce morbidity, preserve organ function and improve
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Table 1. Data quality by country for head and neck cancers diagnosed in 1995–1999 in cancer registries from 17 European countries
Site Country National
coverage (%)
Number
of cases
%HV %DCO-autopsy %Alive with f.u.<5
years (1995–1998)
Men : women
ratio
Mouth and pharynx Northern Europe
Norway 100 1033 98.7 0.4 0.4 2.1
Sweden 100 1884 99.8 0.7 0.2 1.8
UK and Ireland
England 100 12 093 98.8 0.0 0.1 1.9
Northern Ireland 100 431 94.6 0.9 0.0 1.8
Scotland 100 2161 97.2 0.7 0.0 2.0
Wales 100 910 n.a. 6.5 0.0 2.2
Ireland 100 908 94.8 1.7 0.0 2.7
Central Europe
Belgiuma 58.2 1529 96.8 0.1 0.0 3.8
Francea 10.4 3407 99.2b 0.0 3.6 7.0
Germanya 1.3 794 98.7 1.0 7.8 4.2
Switzerlanda 27.0 821 98.1 0.9 2.8 3.4
The Netherlandsa 43.8 1887 99.8 0.1 0.1 1.7
Southern Europe
Italya 9.1 1936 94.6 1.1 1.4 3.3
Spaina 11.4 2149 97.8 0.8 0.6 6.0
Slovenia 100 1099 98.7 0.9 0.2 7.9
Eastern Europe
Czech Republica 8.3 264 97.7 1.9 6.5 3.6
Slovakia 100 3016 92.6 6.2 0.3 12.9
Total 36 322 97.7 1.0 0.8 2.8
Larynx Northern Europe
Denmark 100 1206 98.3 0.2 0.2 4.5
Iceland 100 38 100.0 0.0 0.0 5.4
Norway 100 550 98.9 0.5 0.5 5.8
UK and Ireland
Englanda 23.5 1892 91.7 2.9 4.1 4.7
Northern Ireland 100 315 97.1 0.0 0.0 4.3
Scotland 100 1368 96.3 0.4 0.0 3.8
Wales 100 582 n.a. 3.8 0.0 4.3
Ireland 100 539 95.0 2.0 0.0 5.2
Central Europe
Francea 9.2 1009 98.6b 0.0 5.5 13.4
Germanya 1.3 274 97.8 1.5 9.5 7.1
Switzerlanda 27.0 358 97.5 1.1 3.6 5.0
The Netherlandsa 43.8 1384 99.7 0.1 0.1 5.3
Southern Europe
Italya 8.4 1819 93.5 0.8 2.1 13.1
Malta 100 81 97.5 1.2 0.0 9.1
Spaina 12.9 2429 97.4 1.4 0.5 23.8
Slovenia 100 452 98.5 2.0 0.0 10.6
Eastern Europe
Slovakia 100 1294 92.1 6.8 0.2 18.0
Total 15 590 96.0 1.6 1.5 7.2
aCountries with <100% cancer registration (sometimes because cancer registries were excluded for poor quality data): England: East Anglia, Mersey, South
Western; Belgium: Flanders; France: Bas-Rhin, Calvados, Doubs, Haut-Rhin (mouth and pharynx only), Herault, Isere, Manche, Somme, Tarn; Germany:
Saarland; Switzerland: Basel, Geneva, St. Gallen, Ticino, Valais; The Netherlands: Amsterdam, Eindhoven, North Netherlands, Twente; Italy: Alto Adige,
Biella, Ferrara, Parma (mouth and pharynx only), Ragusa, Reggio Emilia, Romagna, Sassari, Umbria, Varese; Spain: Basque Country, Granada, Murcia,
Navarra, Tarragona (larynx only) Czech Republic: West Bohemia.
bNot available for cases in the registry of Herault.
f.u., follow-up; n.a, not available; HV, histologically verified.
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aesthetic outcomes, while maintaining or improving survival
for these cancers.
The aims of the study were to analyse survival for head and
neck cancers in the European populations covered by the
population-based cancer registries (CRs) participating in
EUROCARE-4, in relation to tumour subsite as prognostic factor
and to assess the extent to which differences in subsite can account
for survival differences between different European populations.
patients and methods
The analysis was confined to adults (age ‡15 years) diagnosed with
malignant epithelial head and neck cancers diagnosed in 1995–1999 and
followed up until 31 December 2003. We excluded adenocarcinomas and
cases occurring after diagnosis of a previous malignancy (except non-
melanoma skin cancer) but included 1.5% of cases without histological
verification. Most cases (94% of mouth and pharyngeal cancers and 86% of
laryngeal cancers) were coded as squamous cell carcinoma (International
Classification of Diseases for Oncology-3 8050-8084) [10]. Of the total of
51912 cancers considered, 15590 affected the larynx (C32.0–C32.9) and
36322 affected the mouth–pharynx, comprising base of tongue (C01.9),
other and unspecified parts of tongue (C02), gum (C03), floor of mouth
(C04), palate (C05), other and unspecified parts of mouth (C06), tonsil
(C09), oropharynx (C10), pyriform sinus (C12.9), hypopharynx (C13), and
other and ill-defined sites of lip, oral cavity and pharynx (C14).
The cases were contributed by 45 selected (see later) population-based
CRs in 20 countries participating in EUROCARE-4. The countries were:
Denmark, Iceland, Norway and Sweden (grouped as Northern Europe); the
Czech Republic and Slovakia (Eastern Europe); Belgium, France, Germany,
The Netherlands and Switzerland (Central Europe); Italy, Malta, Slovenia
and Spain (Southern Europe) and England, Ireland, Northern Ireland,
Scotland and Wales (UK and Ireland).
For 12 participating countries (Denmark, England, Iceland, Ireland,
Malta, Norway, Sweden, Scotland, Wales, Northern Ireland, Slovenia and
Slovakia), the entire population is covered by cancer registration; the
other countries are represented by regional CRs covering variable
proportions of the national population (see footnote of Table 1 for
details).
The CR selection criterion was that the proportion of not otherwise
specified (NOS) cases should be inferior to 30% of the total: NOS laryngeal
(C32.9) and NOS mouth–pharyngeal (02.9, C03.9, C06.9, C10.9, C13.9,
C14.0 and C14.8) sites were considered separately as some registries had few
NOS cases for mouth–pharynx but not for larynx, while the situation was
reversed for other CRs. The choice of 30% was a trade-off between data
quality and number of CRs included in the study.
statistical methods
Survival was expressed as relative survival, calculated as the ratio between
the observed survival and the expected survival in the population of the
same age, sex and country. Relative survival was estimated by the Hakulinen
method [11] using estimates of population life tables for each registry area.
Table 2. Numbers of head and neck cancer cases diagnosed in 1995–1999 by country and anatomical site of origin
Country Tongue C01.9–C02.9 Oral Cavity C3.0-C06.9 Oropharynx C09.0–C10.9 Hypopharynx C12.9–C13.9 Larynx C32.0–C32.9
n %Base %NOS n %Gum
NOS
%Mouth
NOS
n %Tonsil %NOS n %Pyriform
sinus
%NOS n %Glottis %NOS
C01.9 C02.9 C03.9 C06.9 C09 C10.9 C12.9 C13.9 C32.0 C32.9
Northern Europe
Denmark 1206 50.8 11.6
Iceland 38 65.8 21.1
Norway 293 18.4 26.6 358 2.0 7.0 242 77.7 16.9 132 28.0 65.9 550 60.6 7.6
Sweden 503 19.9 0.6 655 4.7 12.4 453 87.1 7.3 260 12.7 77.3
UK and Ireland
England 3667 19.3 46.9 4000 6.3 9.8 2136 76.1 17.1 1564 62.5 14.6 1892 54.5 23.0
Northern Ireland 133 15 36.8 145 6.2 5.5 48 76.1 8.7 64 48.4 12.5 315 47.3 25.1
Scotland 574 23.5 30.3 811 1.2 6.9 335 70.1 17.3 307 58 15.6 1368 44.2 23.0
Wales 297 24.2 29.6 278 6.1 4.7 151 78.4 11.5 123 61 17.9 582 45.7 23.9
Ireland 255 31.8 29 284 3.2 7.8 124 65.9 9.7 176 68.2 9.1 539 58.3 16.3
Central Europe
Belgium 376 28.7 48.4 537 2.2 11.7 342 72.8 18.3 221 66.1 23.1
France 658 41.5 19.5 783 3.2 3.6 916 58.0 7.8 879 73.7 9.2 1009 43.6 10.1
Germany 160 32.5 14.4 258 1.9 1.9 185 65.9 20 151 25.8 54.3 274 47.1 16.8
Switzerland 205 42.4 8.3 213 1.4 3.8 251 62.2 14.8 144 59 29.2 358 60.1 5.3
The Netherlands 472 33.3 4.0 718 0.7 1.0 406 63.6 6.4 277 73.7 6.9 1384 65.7 0.4
Southern Europe
Italy 538 29.7 19.9 544 6.3 10.9 425 59.1 13.7 328 47.3 28.7 1819 56.7 15.2
Malta 81 58.0 14.8
Spain 585 29.6 16.4 655 3.2 7.2 351 53.3 26.5 424 64.6 29.7 2429 39.8 11.0
Slovenia 201 26.4 13.9 258 0.4 1.9 415 37.8 11.3 221 55.2 20.8 452 44.5 8.2
Eastern Europe
Czech Republic 81 38.3 21.0 85 8.2 8.2 70 75.7 11.4 20 5 60.0
Slovakia 711 39.5 5.5 757 0.5 2.1 849 43.0 7.3 657 25.6 17.2 1294 36.6 11.0
Total 9709 26.1 31.8 11 339 4.0 7.9 7699 64.9 13.4 5948 55.3 21.6 15 590 49.7 13.8
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To account for differences in the age distribution of the different
populations, relative survival was adjusted for age by the direct method
using international cancer survival standard age distributions [12].
Relative survival was modelled with a generalised linear model [13], which
assumes the hazards are constant within prespecified subintervals, and implies
a Poisson distribution of the number of observed deaths in each interval. The
models provide estimates of relative excess risks (RER) of death for each
country considering age, sex and anatomic subsite as covariates, applied
separately to mouth–pharyngeal and laryngeal sites. We also ran models
providing estimates of RERs of death for each subsite (mouth–pharyngeal and
laryngeal sites considered separately) with age, sex and country as covariates.
To estimate survival time trends, data from EUROCARE-3 (diagnosis
period 1990–1994) and EUROCARE-4 (diagnosis period 1995–1999) were
compared for CRs that provided data for both periods. Whisker plots was
used to represent survival data over the two study periods. Stata software
[14] was employed to carry out the analyses.
results
Table 1 shows national coverage by site (mouth–pharynx and
larynx), with percentages of cases known by death certificate
only (DCO) and discovered at autopsy, percentages of
histologically verified cases and percentages of cases alive with
follow-up <5 years, as indicators of data quality. DCO/
autoptical cases were excluded from the survival analyses. Table
1 also shows men : women ratios.
For most countries, the percentage of histologically verified
cases ranged between 97% and 100%. Lower percentages were
found for Italy, Ireland and Slovakia for both sites; Northern
Ireland for mouth–pharynx only and England and Scotland for
larynx only.
The proportion of DCO/autoptical cases was high for Wales
(6.5%) and Slovakia (6.2%) for mouth and pharynx; the
percentage lost to follow-up was >6% only for the Czech
Republic (mouth and pharynx) and Germany (larynx).
The male : female ratio was always >1 and was particularly
high for France, Spain, Slovenia and Slovakia (>6 : 1 for mouth
and pharynx and >10 : 1 for larynx); for larynx, the ratio was
also very high for Italy (13 : 1).
Table 2 shows the number of cases by country with the
percentages of cases for the principal anatomical sites and
subsites. The percentage of tongue cancers originating from
base of tongue (26% overall) was highest in France and
Switzerland (>40%) and low in Norway, Sweden, England and
Northern Ireland (<20%). Cancers of the tonsil (65% overall)
accounted for >70% of all oropharyngeal cases in Northern
Europe, the UK, Belgium and the Czech republic, whereas in
Southern Europe, France and Slovakia, they accounted for
<60%. Pyriform sinus cancers (55% overall) accounted for
>70% of all hypopharyngeal cancers in France and The
Netherlands but formed a low proportion of the total in several
other countries, particularly Norway, Sweden, Germany and
Figure 1. Five-year age-standardised relative survival (%) for head and neck cancers by European area and anatomical site of origin.
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the Czech Republic, mainly because of the high proportion of
hypopharyngeal NOS in these latter countries.
Glottic cancers accounted for 40%–60% of all laryngeal
cancers in most countries, the exceptions being Iceland,
Norway, Switzerland, The Netherlands (>60%), Spain and
Slovakia (<40%).
Five-year age-standardised relative survival with 95%
confidence intervals are presented by broad anatomical site and
European region in Figure 1. Northern Europe had the highest
5-year relative survival for tongue, oral cavity and oropharynx
sites, whereas Southern and Central Europe had highest
survival for hypopharynx and larynx sites. For all sites, survival
was lower in Eastern Europe, significantly so for larynx, tongue
and oral cavity.
Table 3 shows 5-year age-standardised relative survival for
the two main sites (mouth–pharynx and larynx) by sex and
country. Survival was better for women in all countries except
Northern Ireland for mouth–pharynx, whereas for larynx, this
was only true for seven countries. Five-year age-standardised
relative survival for mouth–pharynx ranged from 17%
(Slovakia) to 49% (The Netherlands) for men and from 28%
(Slovakia) to 61% (Germany) for women. Survival was better
for larynx: rates ranged between 39% (Slovakia) and 78% (The
Netherlands) for men and between 52% (Denmark) and 78%
(Slovenia) for women. Thus, for both sites, survival was
particularly low in Slovakia and high in The Netherlands.
Models estimating RERs of death are shown in Table 4
(mouth–pharynx) and Table 5 (larynx): Model 1 has age at
diagnosis and sex as covariates; model 2 has age, sex and
anatomical subsite as covariates. For mouth–pharynx (Table 4),
by model 1, Sweden and The Netherlands had significantly
lower RERs of dying than England (reference), while Northern
Ireland, Ireland, France, Slovenia, the Czech Republic and
Slovakia had significantly higher RERs of dying than reference.
After adjustment for anatomical subsite (model 2), RERs of
dying for Italy and Germany became significantly lower than
for England, whereas the RER for France was no longer
significantly higher.
With regard to subsite, the RER of dying was highest for the
postcricoid region (1.70) and lowest for cheek plus vestibule of
mouth (0.53) compared with reference (base of tongue plus
vallecula plus lingual tonsil).
For larynx (Table 5), RERs of dying in Italy and The
Netherlands were significantly lower than England; while
Slovakia, France, Denmark, Ireland, Wales and Scotland had
significantly higher RERs of dying than England (model 1).
After adjustment for anatomical subsite (model 2), RERs
remained high only for Slovakia, Ireland, Denmark and France.
RERs of dying were higher than reference (glottis) for all
anatomical subsites considered.
Analysing men and women separately (data not shown), we
found that for most countries RERs were similar to those shown
Table 3. Five-year age-standardised relative survival (RS) (%) by country and sex for European patients diagnosed with mouth and pharyngeal and
laryngeal cancers in 1995–1999 and archived cancer registries from 17 countries
Country Mouth and pharynx Larynx
Men Women Men Women
Five-year age-standardised RS Five-year age-standardised RS Five-year age-standardised RS Five-year age-standardised RS
Northern Europe
Denmark 61.1 (51.5–70.2) 52.0 (34.3–67.3)
Iceland 59.0 (16.0–100.0) Value not calculable
Norway 37.4 (28.4–46.9) 47.5 (34.0–60.0) 66.2 (52.6–77.7) 71.1 (39.8–92.5)
Sweden 42.5 (35.4–49.6) 52.8 (43.2–61.3)
UK and Ireland
England 38.4 (35.6–41.2) 45.5 (41.7–49.1) 69.7 (62.3–76.5) 61.4 (48.8–72.5)
Northern Ireland 33.4 (20.1–48.2) 33.2 (15.9–52.2) 65.5 (46.2–82.0) Value not calculable
Scotland 40.1 (32.7–47.7) 46.0 (36.5–55.2) 65.3 (55.3–73.9) 59.8 (46.3–72.4)
Wales 37.3 (27.1–48.2) 42.4 (27.9–56.5) 62.6 (49.0–74.6) 64.4 (42.4–81.8)
Ireland 33.8 (24.6–43.9) 41.0 (26.2–55.6) 62.1 (47.9–73.7) 57.3 (29.0– 80.7)
Central Europe
Belgium 34.0 (27.0–41.6) 45.1 (31.2–58.7)
France 30.6 (25.9–35.6) 48.7 (36.8–60.3) 55.2 (45.8–64.4) 56.9 (26.9–81.8)
Germany 44.1 (30.9–58.2) 61.0 (37.1–81.8) 59.4 (39.1–79.4) 59.7 (24.4–91.3)
Switzerland 35.8 (25.5–47.2) 48.5 (29.5–66.3) 62.7 (45.6–77.5) 56.6 (31.6–79.9)
The Netherlands 49.4 (40.7–58.2) 53.6 (43.5–63.3) 78.2 (69.4–85.8) 66.9 (48.8–81.7)
Southern Europe
Italy 37.4 (30.8–44.3) 48.9 (37.0–60.0) 74.2 (66.9–80.4) 67.5 (43.5–85.5)
Malta 75.0 (37.4–100.0) Value not calculable
Spain 36.5 (30.1–43.4) 53.1 (39.2–65.7) 64.6 (58.5–70.4) 71.2 (42.1–91.1)
Slovenia 23.8 (16.8–33.7) 56.2 (29.8–79.9) 62.4 (45.6–79.3) 77.7 (28.3–100.0)
Eastern Europe
Czech 33.4 (11.4–63.4) 48.5 (20.6–77.9)
Slovakia 17.2 (11.9–23.9) 28.0 (12.3–48.7) 38.9 (29.7–49.1) 53.0 (23.9–84.1)
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in Table 4 (mouth–pharynx) for men and women together.
However, for women alone, the differences in RERs of death
between the Czech Republic, Ireland, Slovenia and England for
mouth and pharynx were no longer evident. For larynx, RERs of
death for men in Norway and Switzerland were significantly
higher than that in England, while for The Netherlands, the RER
was similar to reference. For women, RERs of death for larynx
were similar to reference (England) for most countries except
Italy (significantly lower) and Slovakia (significantly higher).
Country-specific 5-year relative survival was greater in 1995–
1999 than in 1990–1994 for larynx and slightly greater also for
mouth and pharynx (Figure 2).
Table 4. (A) RERs of death by country for all mouth–pharynx sites adjusted by age and sex (model 1) and by age, sex and subsite (model 2) compared
with England. (B) RERs of death by subsite relative to base of tongue plus vallecula plus lingual tonsil (reference) with age, sex and country as
covariates
(A) Country Model 1 Model 2
RER of death adjusted
for age and sex
95% CI RER of death adjusted
for age, sex and subsite
95% CI
Northern Europe
Norway 0.94 0.86–1.03 0.97 0.88–1.06
Sweden 0.80 0.75–0.86 0.82 0.76–0.88
UK and Ireland
England (Reference) 1 (Reference) 1
Northern Ireland 1.28 1.12–1.45 1.25 1.10–1.42
Scotland 1.01 0.95–1.08 1.01 0.95–1.07
Wales 1.00 0.91–1.10 0.99 0.89–1.09
Ireland 1.19 1.08–1.30 1.12 1.01–1.22
Central Europe
Belgium 1.06 0.99–1.14 1.03 0.96–1.11
France 1.15 1.09–1.21 1.01 0.96–1.07
Germany 0.90 0.81–1.00 0.83 0.74–0.92
Switzerland 1.00 0.91–1.11 0.94 0.85–1.03
The Netherlands 0.82 0.76–0.88 0.83 0.77–0.89
Southern Europe
Italy 0.94 0.88–1.00 0.89 0.83–0.95
Spain 1.04 0.97–1.11 0.97 0.91–1.03
Slovenia 1.36 1.26–1.48 1.26 1.16–1.37
Eastern Europe
Czech Republic 1.52 1.30–1.80 1.47 1.26–1.73
Slovakia 2.40 2.28–2.53 2.16 2.05–2.28
(B) Subsite ICD-O-3 code %
Base of tongue, vallecula and
lingual tonsil
C01.9, C02.4, C02.8, C10.0 9.7 (Reference) 1
Tongue, other parts C02.0–C02.3, C02.9 18.4 0.59 0.55–0.62
Gum C03.0–C03.9 4.9 0.60 0.55–0.66
Floor of mouth C04.0–C04.9 12.7 0.64 0.6–0.68
Palate C05.0–C05.9 5.0 0.68 0.63–0.73
Cheek and vestibule of mouth C06.0–C06.1 3.2 0.53 0.47–0.58
Retromolar area C06.2 2.7 0.65 0.59–0.72
Mouth, NOS C06.8–C06.9 2.8 0.79 0.71–0.87
Tonsil C09.0–C09.9 13.8 0.72 0.67–0.76
Anterior surface of epiglottitis C10.1 0.5 0.76 0.61–0.94
Lateral wall of oropharynx C10.2, C10.8 2.4 0.99 0.90–1.09
Posterior wall of oropharynx C10.3 0.4 1.60 1.33–1.93
Oropharynx and pharynx, NOS C10.9, C14.0, C14.8 7.1 1.45 1.36–1.54
Pyriform sinus and posterior
wall of hypopharynx
C12.9, C13.2 9.7 1.16 1.09–1.23
Aryepiglottic fold C13.1 0.8 0.87 0.75–1.02
Postcricoid region C13.0 1.4 1.70 1.52–1.91
Hypopharynx, NOS C13.8–C13.9 4.5 1.50 1.40–1.61
CI, confidence interval; ICD-O, International Classification of Diseases for Oncology; NOS, not otherwise specified; RERs, relative excess risks.
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discussion
Consistent with previous population-based findings [9], the
present study found that survival varied markedly with subsite.
Thus, among mouth–pharynx sites, hypopharynx, base of
tongue, lateral and posterior wall of the oropharynx (Table 4)
were characterised by relatively poor survival, while among
laryngeal sites, the supraglottic and subglottic subsites had poor
survival (Table 5).
Since the distribution of subsites in European countries is
not homogeneous, we expected the marked geographic
differences in survival that we in fact found (Figure 1).
However, important survival differences persisted even after
correcting for subsite distribution. In particular, considering
mouth–pharynx subsites, age- and sex-adjusted RERs of death
were similar in Norway, England, Scotland, Wales, Belgium,
Germany, Switzerland, Italy and Spain, but significantly higher
in Slovakia and the Czech Republic, and to a lesser extent also
in Slovenia, France, Northern Ireland and Ireland (Table 4,
model 1). RERs of death continued to be significantly higher in
these latter countries, except France, even after correcting for
subsite distribution (Table 4, model 2). We may, therefore,
provisionally attribute poor survival in these latter countries to
poor access to good treatment or late diagnosis.
Adjustment for subsite reduced RERs of death for most
countries. Exceptions were the other UK countries, The
Netherlands and Northern European countries–all
characterised by lower frequencies of poor prognosis subsites
(hypopharynx, base of tongue and oropharynx except tonsil).
In France, where prognosis was fairly poor, subsite adjustment
made the RER of death similar to that of England; in Italy and
Germany, subsite adjustment made the prognosis significantly
better than England.
Turning now to laryngeal sites, we note that most countries
had similar prognoses after subsite adjustment. However,
Slovakia, Denmark, Ireland and France continued to have
significantly higher RERs of death than reference after subsite
adjustment (Table 5, model 2), again suggesting late diagnosis
or poor access to good treatment in these countries.
Nevertheless, RERs decreased following subsite adjustment in
Slovakia and France (as well as in Spain, Germany, Slovenia,
Scotland and Wales) also reflecting low frequencies of relatively
good prognosis glottic cancers (compared with reference) in
these countries (Table 2).
Table 5. (A) RERs of death by country for all laryngeal sites adjusted by age and sex (model 1) and by age, sex and subsite (model 2) compared with
England. (B) RERs of death by subsite relative to glottis, with age, sex and country as covariates
(A) Country Model 1 Model 2
RER of death adjusted
for age and sex
95% CI RER of death adjusted
for age sex and subsite
95% CI
Northern Europe
Denmark 1.38 1.20–1.59 1.30 1.13–1.50
Iceland 0.95 0.47–1.93 1.00 0.49–2.12
Norway 1.03 0.84–1.25 1.19 0.98–1.44
UK and Ireland
England (Reference) 1 (Reference) 1
Northern Ireland 1.11 0.87–1.41 0.99 0.78–1.25
Scotland 1.21 1.05–1.39 1.06 0.92–1.22
Wales 1.22 1.01–1.46 1.00 0.83–1.21
Ireland 1.33 1.1–1.6 1.43 1.19–1.71
Central Europe
France 1.54 1.34–1.78 1.3 1.12–1.5
Germany 1.20 0.93–1.54 1.00 0.77–1.29
Switzerland 1.11 0.89–1.39 1.24 0.99–1.55
The Netherlands 0.71 0.6–0.85 0.84 0.71–0.99
Southern Europe
Italy 0.81 0.7–0.93 0.78 0.68–0.9
Malta 1.00 0.64–1.59 1.06 0.68–1.66
Spain 1.13 1.00–1.29 0.89 0.79–1.01
Slovenia 1.21 0.99–1.49 1.04 0.84–1.28
Eastern Europe
Slovakia 2.57 2.26–2.92 2.21 1.94–2.52
(B) Subsite ICD-O-3 code %
Glottis C32.0 50.8 (Reference) 1
Supraglottis C32.1 29.5 3.80 3.50–4.12
Subglottis C32.2 1.5 3.63 2.94–4.48
Overlapping areas of larynx C32.8 5.6 4.08 3.62–4.61
Larynx, NOS C32.9 12.6 4.07 3.69–4.49
CI, confidence interval; ICD-O, International Classification of Diseases for Oncology; NOS, not otherwise specified; RERs, relative excess risks.
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Another possible reason for between-country differences in
survival—even after subsite adjustment—is cancer site
misclassification. Thus, possible misclassification of the good
prognosis glottic site versus poor prognosis supraglottic,
subglottic or NOS sites (Table 5) is suggested by the relatively
high proportion of ‘overlapping’ sites, in turn probably
reflecting the difficulty of identifying the primary subsite in the
presence of locally advanced disease.
Other factors influencing survival in head and neck cancers
are stage [15], comorbidity [16] and patient socioeconomic
status at least in the first 12–18 months following diagnosis
[17].
As regards stage, it is noteworthy that subsite determines the
appearance of symptoms, which in turn influences stage at
diagnosis [9]. As regards comorbidity, data suggest that this
factor exerts its greatest effects on patients with good
prognostic factors (tongue or glottic sites, early-stage disease
and young age) [18].
Socioeconomic status exerts its greatest effects on laryngeal
cancers, where survival differences between deprived and
affluent groups are greater than for any other common cancer
[19, 20]. A study on survival trends for laryngeal sites in
England and Wales found that the overall increase in 5-year
survival between 1986–1990 and 1996–1999 occurred
exclusively in the most affluent sector of the population [21].
In the present study, we had no information on stage,
comorbidity or socioeconomic status and no means to estimate
the effect of confounding by misclassification. It is difficult,
therefore, to account for all factors contributing to the survival
differences for European head and neck cancer patients
revealed by this study. Nevertheless, it is clear that differences in
subsite distribution explain a considerable part of the survival
differences, from which an important message emerges:
survival comparisons require careful adjustment for anatomical
subsite, so it is essential that CRs take steps to ensure that
subsite information is accurate and complete.
Another important finding of this study is that 5-year relative
survival increased from 1990–1994 to 1995–1999 for all types of
head and neck cancer. These European results are encouraging
because they are not mirrored by similar analysis conducted in the
United States in particular for laryngeal cancer [22]. Finally, we
note that survival differences between countries decreased from
1990–1994 to 1995–1999, suggesting reductions in inequalities of
treatment quality and treatment access across Europe.
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Figure 2. Changes in 5-year country-specific age-standardised relative survival for mouth–pharyngeal and laryngeal sites from 1990–1994 to 1995–1999.
Only countries whose registries contributed data for both periods are included.
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